DEVELOPING A HOLISTIC GLP-1 STRATEGY
We take an evidence-based approach to GLP-1 drugs, working with our partners to develop individualized strategies that promote clinically appropriate use and consider total cost of care, long-term value and member health outcomes.
PRESS RELEASES
GLP-1 year-2 real-world data
Prime Therapeutics LLC/Magellan Rx Management, LLC (Prime/MRx) continues to lead the industry with a new analysis of real-world integrated pharmacy and medical claims data, which shows 85% of individuals who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for weight loss were no longer taking the drug after two years. This analysis is a follow-up to research presented by Prime/MRx in 2023, which found that 71% of individuals were no longer taking these drugs for weight loss at one year, representing a further 14% point decrease in persistence in just one year.
CLINICAL PERSPECTIVES
The evolution of GLP-1s
When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend.² So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program. You can learn more about the latest GLP-1 trends, the drug pipeline and ways to capitalize on new opportunities.
Clinical insights
Holistic solutions for weight management
Obesity has grown in prevalence over recent decades, with nearly 73.1% of adults in the U.S. who are either overweight or obese. In addition to the health impact obesity can have, it’s also costing the health care system almost $173B per year. We’ve published a new white paper outlining where we are today and how things are shaping up for the future, demystifying trends like GLP-1s and providing our expert perspective on what it takes to deliver a whole-person approach to sustainable weight management.
KEEPWELL™
Next-level cardiometabolic support
Conditions like obesity, diabetes, hypertension and high cholesterol can compound if left unchecked, causing serious and costly health problems. KeepWell offers a personalized and effective path to wellness for your members, driving better outcomes across the cardiometabolic spectrum.
PODCASTS
Hear from our GLP-1 experts
Year-one data
REAL-WORLD ANALYSIS
The impact of GLP-1s
Glucagon-like peptide-1 agonists, or GLP-1s, have historically been used to manage type 2 diabetes. But there has also been a substantial increase in people using these drugs for weight loss, causing demand to skyrocket. In a recent study, Prime Therapeutics and Magellan Rx found only 27% of individuals were still using GLP-1s for weight loss a year after they began treatment – and revealed increased health care costs of $7,727 per person.1 As GLP-1s continue to transform the health care landscape, we offer clinical experts who help our partners stay on the forefront of this dynamic trend, delivering trusted, evidence-based insights.
Stay on top of the latest news
Regular updates from our newsroom
Stories
July 22, 2024
Introducing the latest issue of our medical and pharmacy benefit management report
The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care
In the news
July 12, 2024
Study Shows 85% Of Patients Discontinue GLP-1s For Weight Loss After 2 Years
Forbes
1 Internal analysis, 2023
2 Internal analysis, 2023, based on GLP-1 list prices at time of publishing, including but not limited to Wegovy and Zepbound
3 Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9. Medication and weight-loss is for people living with type 2 diabetes and completing 1 year. Medication reduction refers to the percent of total diabetes prescriptions eliminated, excluding metformin.
4 McKenzie AL, Athinarayanan SJ, McCue JJ, Adams RN, Keyes M, McCarter JP, Volek JS, Phinney SD, Hallberg SJ. Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study. Nutrients. 2021; 13(3):749.